Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Impression Healthcare has successfully registered its first clinical trial to investigate the effects of its Cannabidiol (CBD) toothpaste and mouthwash on Gum Disease
  • The trial is a world first for the assessment of CBD on Gingivitis and Periodontitis
  • Approximately five million Australians and almost 40 per cent of Australians aged 55 and over have moderate to severe gum disease or Periodontitis
  • Registration of the trial marks the formal commencement of the trial as per Impression’s commitment with Cannvalate
  • Three other clinical trials for the investigation of cannabis medicines into sleep apnoea, concussion remediation and TMJ Disorders are also progressing and on track to commence in Q3 CY2019
  • IHL will now formalise approval from the Human Research Ethics Committee, prior to patient recruitment and dosing

Impression Healthcare has successfully registered its first clinical trial to investigate the effects of its Cannabidiol (CBD) toothpaste and mouthwash on Gum Disease.

The completed trial protocol has been submitted to and registered on the Australian and New Zealand Clinical Trials Registry (ANZCTR). The company will now formalise all approvals before recruiting and dosing patients.

“Formal registration of the gingivitis and periodontitis trialrepresents significant progress in IHL’s medicinal cannabis activities and is the culmination of many months of work by our team and research partners,” CEO Joel Latham, said.

The trial is considered a phase 2a randomised controlled clinical trial designed to investigate clinical efficacy and safety.

Approximately five million Australians and almost 40 per cent of Australians aged 55 and over have moderate to severe gum disease or Periodontitis.

The trial will comprise 40 participants who will use the CBD toothpaste and mouthwash three times daily over a 30-day period. Gum inflammation will initially be induced and then monitored as Cannabidiol is a powerful suppressor of inflammation.

After five days of treatment, the patients’ gum health will be measured using the gingivitis bleeding index and then again after the 30-day trial period.

IHL is working with AXIM Biotechnologies Incorporated who will provide the products for the clinical trials and also facilitate commercial sales under a royalty arrangement.

In March 2019, IHL executed a binding collaboration agreement with Cannvalate and Swinburne University of Technology to undertake four medicinal cannabis clinical trials. The trials include using Cannabidiol for the treatment of Temporomandibular Joint Dysfunction (TJD), concussions, sleep apnoea and gum disease.

“We are excited to have assembled highly qualified researchers for a world first trial for the use of CBD in treatment of Gingivitis and Gum Disease, which are major problems representing a major market,” Joel said.

Patient recruitment for the gum disease trials will commence in August followed by the 30-day trial.

IHL by the numbers
More From The Market Herald
The Market Herald Video

" Next Science’s (ASX:NXS) CEO submits resignation

Next Science’s (ASX:NXS) CEO has announced her intention to retire before June 30, 2023.
The Market Herald Video

" Race Oncology (ASX:RAC) completes first-phase Zantrene leukaemia trial

Cancer treatment company Race Oncology (ASX:RAC) has completed the latest stage of its first-phase trial for…
The Market Herald Video

" Immutep (ASX:IMM) publishes “favourable” interim data from second-phase efti trial

Immutep (ASX:IMM) has published new interim data from Part A of its second-phase TACTI-002 trial showing…

" Microba Life Sciences (ASX:MAP) partners with Midnight Health

Microba Life Sciences (ASX:MAP) has signed a strategic partnership agreement with healthcare company, Midnight Health, to…